Compare Inovio Pharmaceuticals Inc (INO) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Alliant Energy Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while Alliant Energy Corporation trades at $65.58 (market cap $16.99B). The key difference: Alliant Energy Corporation is far larger — about 151.4× Inovio Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Alliant Energy Corporation for 64 Days on average.
| INO | LNT | |
|---|---|---|
Market Cap | $112.19M | $16.99B |
Volume | 3,201,278 | 2,488,387 |
Sector | Health | Utilities |
52-Week High | $2.65 | $78.03 |
52-Week Low | $0.66 | $63.21 |
Typical Hold Time | 43 Days | 64 Days |
Enterprise Value | $83.51M | $29.08B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
LNT trades at $65.21, down 0.43% on the day, with a bullish technical signal despite mixed indicators. The company reported Q2 2026 EPS of $0.65, beating estimates, and maintains a strong profitability profile with an 18.45% net income margin. Recent news highlights institutional buying and a $1.4 billion partnership expansion, though the stock recently touched a 52-week low.
The outlook is supported by a $13.4 billion capital investment plan and data center demand growth, offering potential upside to the $77 consensus price target. Risks include rising debt levels and cost pressures, but analyst sentiment remains positive with no sell ratings. The stock presents a defensive income opportunity with a growing dividend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
